Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Prevention of venous thromboembolism among hospitalized medical patients.Circulation. 2005; 111: e1-e3
- Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.Arch Intern Med. 2002; 162: 1245-1248
- Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer.Thromb Haemost. 2014; 112: 255-263
- The epidemiology of venous thromboembolism.J Thromb Thrombolysis. 2016; 41: 3-14
- Deep vein thrombosis: a clinical review.J Blood Med. 2011; 2: 59-69
- Medicine of the Future : Risk Assessment , Elimination or Mitigation , and Action Plans for 28 Diseases and Medical Conditions .Springer International Publishing, 2016 (New York)
US Department of Health and Human Services. The Surgeon General's call Call to action Action to prevent Prevent deep Deep vein Vein thrombosis Thrombosis and pulmonary Pulmonary Embolism. Washington, D.C., 2008.
- A comparison of Enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients.N Engl J Med. 1999; 341: 793-800
- Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.BMJ. 2006; 332: 325-329
- A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis.N Engl J Med. 1998; 338: 409-416
- Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study.BMJ. 1998; 316: 17-20
- Diagnosis and treatment of deep-vein thrombosis.CMAJ. 2006; 175: 1087-1092
- Developing public health surveillance for deep vein thrombosis and pulmonary embolism.Am J Prev Med. 2011; 41: S428-S434
- Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop.Am J Prev Med. 2010; 38: S502-S509
- Epidemiology and prevention of deep vein thrombosis.In: Bounomeaux H, Le Gal, Eds. Current Approaches to Deep Vein Thrombosis. Future Medicine Ltd, . 2014; : 6-22
- Iatrogenic disease in the elderly: risk factors, consequences, and prevention.Clin Interv Aging. 2011; 6: 77-82
- Older people's and relatives’ experiences in acute care settings: systematic review and synthesis of qualitative studies.Int J Nurs Stud. 2010; 47: 89-107
- The role of ethnicity, age and gender in venous thromboembolism.J Thromb Thrombolysis. 2010; 29: 489-496
- Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States.Thromb Res. 2010; 126: 61-67
- An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure.Circulation. 2006; 113: 1693-1701
- Checking the Cox model with cumulative sums of martingale-based residuals.Biometrika. 1993; 80: 557-572
- National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010.Circulation. 2013; 128: 2577-2584
- Declining long-term risk of adverse events after first-time community-presenting venous thromboembolism: the population-based Worcester VTE Study (1999 to 2009).Thromb Res. 2015; 135: 1100-1106
- Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012; 141: e419S-e494S
- The contribution of immobility risk factors to the incidence of venous thrombosis in an older population.J Thromb Haemost. 2014; 12: 290-296
- Call to action to prevent venous thromboembolism.J Vasc Surg. 2009; 49: 1620-1623
- Electronic alerts to prevent venous thromboembolism among hospitalized patients.N Engl J Med. 2005; 352: 969-977
- National trends in pulmonary embolism hospitalization rates and outcomes for adults aged ≥65 Years in the United States (1999 to 2010).Am J Cardiol. 2015; 116: 1436-1442
- Effects of race and ethnicity on the incidence of venous thromboembolism.Thromb Res. 2009; 123: S11-S17
- An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure.Circ Cardiovasc Qual Outcomes. 2008; 1: 29-37
- Lifetime risk of venous thromboembolism in two cohort studies.Am J Med. 2016; 129 (339): e19-e26
- Gender and ethnic/racial disparities in health care utilization among older adults.J Gerontol B Psychol Sci Soc Sci. 2002; 57: S221-S233
- Overlooked and underserved: improving the health of men of color.Am J Public Health. 2008; 98: S139-S141
- According to him: barriers to healthcare among African-American men.J Natl Med Assoc. 2008; 100: 1153-1160
- Racial differences in the use of cardiac catheterization after acute myocardial infarction.N Engl J Med. 2001; 344: 1443-1449
- Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients.Am J Cardiol. 2005; 95: 1525-1526
- Trends in prevalence of deep venous thrombosis among hospitalised patients in an Asian institution.Thromb Haemost. 2009; 101: 1095-1099
- DVT management and outcome trends, 2001 to 2014.Chest. 2016; 150: 374-383
Funding: This work was supported by grant number U01 HL105270-06 from the National Heart, Lung, and Blood Institute at the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of National Institutes of Health.
Conflicts of Interest: BB is supported by the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) through grant number T32 HL007854. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. BB and HMK report that they were approached by lawyers on behalf of plaintiffs in litigation related to IVC filters, although this study was conducted prior to that relationship. The current study is the idea of the investigators and not performed at the request or support of a third party. HMK is a recipient of research grants, through Yale, from Medtronic and Johnson & Johnson (Janssen) to develop methods of clinical trial data sharing and from Medtronic and the U.S. Food and Drug Administration to develop methods for post-market surveillance of medical devices; works under contract with the Centers for Medicare & Medicaid Services to develop and maintain performance measures that are publicly reported; chairs a Cardiac Scientific Advisory Board for UnitedHealth; is a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science and the Physician Advisory Board for Aetna; and is the founder of Hugo, a personal health information platform. KEM, YW, and RRA have no conflicts, financial or otherwise, to disclose.
Authorship: HMK takes full responsibility for the content of the manuscript including the data and analysis. KEM, BB, YW, and RRA contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript.